SB-258719 is a drug developed by GlaxoSmithKline which acts as a selective 5-HT7 receptor partial inverse agonist, and was the first such ligand identified for 5-HT7. Its use in research has mainly been in demonstrating the potential use for 5-HT7 agonists as potential novel analgesics, due to the ability of SB-258719 to block the analgesic effects of a variety of 5-HT7 agonists across several different testing models.
Property | Value |
---|---|
dbo:abstract |
|
dbo:casNumber |
|
dbo:chEMBL |
|
dbo:pubchem |
|
dbo:thumbnail | |
dbo:wikiPageID |
|
dbo:wikiPageLength |
|
dbo:wikiPageRevisionID |
|
dbo:wikiPageWikiLink | |
dbp:c |
|
dbp:casNumber |
|
dbp:chembl |
|
dbp:chemspiderid |
|
dbp:h |
|
dbp:iupacName |
|
dbp:iupharLigand |
|
dbp:n |
|
dbp:o |
|
dbp:pubchem |
|
dbp:s |
|
dbp:smiles |
|
dbp:stdinchi |
|
dbp:stdinchikey |
|
dbp:verifiedfields |
|
dbp:verifiedrevid |
|
dbp:width |
|
dbp:wikiPageUsesTemplate | |
dcterms:subject | |
gold:hypernym | |
rdf:type |
|
rdfs:comment |
|
rdfs:label |
|
owl:sameAs | |
prov:wasDerivedFrom | |
foaf:depiction | |
foaf:isPrimaryTopicOf | |
is dbo:wikiPageRedirects of | |
is dbo:wikiPageWikiLink of | |
is foaf:primaryTopic of |